ReviewTranslational neuroscience2021
Effects of gut microbiota and probiotics on Alzheimer's disease.
Review in Translational neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- The Role of Probiotics in Modulating the Gut Microbiome in Alzheimer's Disease: A Review.Foods (Basel, Switzerland) · 2025Review
- A Novel Effect of Id2 in Microglia TNFα Regulation.Molecular neurobiology · 2025Article
- The gut-brain axis in Alzheimer's disease: how gut microbiota modulate microglial function.Frontiers in aging · 2025Review
- Protective Effects of Heat-KilledJournal of microbiology and biotechnology · 2024Article
- Gut dysbiosis mediates the association between antibiotic exposure and chronic disease.Frontiers in medicine · 2024Review
- Modulation of gut microbiota with probiotics as a strategy to counteract endogenous and exogenous neurotoxicity.Advances in neurotoxicology · 2024Article
- Alleviation of Cognitive Impairment-like Behaviors, Neuroinflammation, Colitis, and Gut Dysbiosis in 5xFAD Transgenic and Aged Mice byNutrients · 2023Article
- Alleviation ofNutrients · 2023Article
- Implications of Microorganisms in Alzheimer's Disease.Current issues in molecular biology · 2022Review
- Clinical and Preclinical Studies of Fermented Foods and Their Effects on Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2022Review
- Efficacy ofGut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease with high morbidity, disability, and fatality rate, significantly increasing the global burden of public health. The failure in drug discovery over the past decades has stressed the urgency and importance of seeking new perspectives. Recently, gut microbiome (GM), with the ability to communicate with the brain bidirectionally through the microbiome-gut-brain axis, has attracted much attention in AD-related studies, owing to their strong associations with amyloids, systematic and focal inflammation, impairment of vascular homeostasis and gut barrier, mitochondrial dysfunction, etc., making the regulation of GM, specifically supplementation of probiotics a promising candidate for AD treatment. This article aims to review the leading-edge knowledge concerning potential roles of GM in AD pathogenesis and of probiotics in its treatment and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.